Literature DB >> 11064361

Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse.

K Van Pett1, V Viau, J C Bittencourt, R K Chan, H Y Li, C Arias, G S Prins, M Perrin, W Vale, P E Sawchenko.   

Abstract

Two G protein-coupled receptors have been identified that bind corticotropin-releasing factor (CRF) and urocortin (UCN) with high affinity. Hybridization histochemical methods were used to shed light on controversies concerning their localization in rat brain, and to provide normative distributional data in mouse, the standard model for genetic manipulation in mammals. The distribution of CRF-R1 mRNA in mouse was found to be fundamentally similar to that in rat, with expression predominating in the cerebral cortex, sensory relay nuclei, and in the cerebellum and its major afferents. Pronounced species differences in distribution were few, although more subtle variations in the relative strength of R1 expression were seen in several forebrain regions. CRF-R2 mRNA displayed comparable expression in rat and mouse brain, distinct from, and more restricted than that of CRF-R1. Major neuronal sites of CRF-R2 expression included aspects of the olfactory bulb, lateral septal nucleus, bed nucleus of the stria terminalis, ventromedial hypothalamic nucleus, medial and posterior cortical nuclei of the amygdala, ventral hippocampus, mesencephalic raphe nuclei, and novel localizations in the nucleus of the solitary tract and area postrema. Several sites of expression in the limbic forebrain were found to overlap partially with ones of androgen receptor expression. In pituitary, rat and mouse displayed CRF-R1 mRNA signal continuously over the intermediate lobe and over a subset of cells in the anterior lobe, whereas CRF-R2 transcripts were expressed mainly in the posterior lobe. The distinctive expression pattern of CRF-R2 mRNA identifies additional putative central sites of action for CRF and/or UCN. Constitutive expression of CRF-R2 mRNA in the nucleus of the solitary tract, and stress-inducible expression of CRF-R1 transcripts in the paraventricular nucleus may provide a basis for understanding documented effects of CRF-related peptides at a loci shown previously to lack a capacity for CRF-R expression or CRF binding. Other such "mismatches" remain to be reconciled. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11064361     DOI: 10.1002/1096-9861(20001211)428:2<191::aid-cne1>3.0.co;2-u

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  403 in total

1.  Urocortin III-immunoreactive projections in rat brain: partial overlap with sites of type 2 corticotrophin-releasing factor receptor expression.

Authors:  Chien Li; Joan Vaughan; Paul E Sawchenko; Wylie W Vale
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

2.  Chronic anabolic androgenic steroid exposure alters corticotropin releasing factor expression and anxiety-like behaviors in the female mouse.

Authors:  Beth A Costine; Joseph G Oberlander; Matthew C Davis; Carlos A A Penatti; Donna M Porter; Robert N Leaton; Leslie P Henderson
Journal:  Psychoneuroendocrinology       Date:  2010-05-26       Impact factor: 4.905

3.  Chronic oxytocin-driven alternative splicing of Crfr2α induces anxiety.

Authors:  Erwin H van den Burg; Benjamin Jurek; Inga D Neumann; Julia Winter; Magdalena Meyer; Ilona Berger; Melanie Royer; Marta Bianchi; Kerstin Kuffner; Sebastian Peters; Simone Stang; Dominik Langgartner; Finn Hartmann; Anna K Schmidtner; Stefan O Reber; Oliver J Bosch; Anna Bludau; David A Slattery
Journal:  Mol Psychiatry       Date:  2021-05-25       Impact factor: 15.992

4.  Activation of corticotropin-releasing factor receptor 2 mediates the colonic motor coping response to acute stress in rodents.

Authors:  Guillaume Gourcerol; S Vincent Wu; Pu-Qing Yuan; Hung Pham; Marcel Miampamba; Muriel Larauche; Paul Sanders; Tomofumi Amano; Agata Mulak; Eunok Im; Charalabos Pothoulakis; Jean Rivier; Yvette Taché; Mulugeta Million
Journal:  Gastroenterology       Date:  2011-01-26       Impact factor: 22.682

5.  Central infusion of ovine CRF (oCRF) potentiates defensive behaviors in CD-1 mice in the Mouse Defense Test Battery (MDTB).

Authors:  Mu Yang; Catherine Farrokhi; Amy Vasconcellos; Robert J Blanchard; D Caroline Blanchard
Journal:  Behav Brain Res       Date:  2006-04-18       Impact factor: 3.332

6.  CRF₂ mediates the increased noradrenergic activity in the hypothalamic paraventricular nucleus and the negative state of morphine withdrawal in rats.

Authors:  Javier Navarro-Zaragoza; Cristina Núñez; Jessica Ruiz-Medina; M Luisa Laorden; Olga Valverde; M Victoria Milanés
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

7.  Differential expression of 5HT-1A, alpha 1b adrenergic, CRF-R1, and CRF-R2 receptor mRNA in serotonergic, gamma-aminobutyric acidergic, and catecholaminergic cells of the rat dorsal raphe nucleus.

Authors:  Heidi E W Day; Benjamin N Greenwood; Sayamwong E Hammack; Linda R Watkins; Monika Fleshner; Steven F Maier; Serge Campeau
Journal:  J Comp Neurol       Date:  2004-06-28       Impact factor: 3.215

8.  DTI-identified microstructural changes in the gray matter of mice overexpressing CRF in the forebrain.

Authors:  Jessica Deslauriers; Mate Toth; Miriam Scadeng; Benjamin S McKenna; Robert Bussell; Jodi Gresack; Robert Rissman; Victoria B Risbrough; Gregory G Brown
Journal:  Psychiatry Res Neuroimaging       Date:  2020-07-15       Impact factor: 2.376

9.  Contrasting effects of pretraining, posttraining, and pretesting infusions of corticotropin-releasing factor into the lateral amygdala: attenuation of fear memory formation but facilitation of its expression.

Authors:  Koichi Isogawa; David E A Bush; Joseph E LeDoux
Journal:  Biol Psychiatry       Date:  2012-10-01       Impact factor: 13.382

10.  A sexually dimorphic distribution of corticotropin-releasing factor receptor 1 in the paraventricular hypothalamus.

Authors:  Zachary J Rosinger; Jason S Jacobskind; Rose M De Guzman; Nicholas J Justice; Damian G Zuloaga
Journal:  Neuroscience       Date:  2019-05-02       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.